Victory Capital Management’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Victory Capital Management’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-8,989	Closed	-$217K	–	2659
2023 Q1	$217K	Sell	8,989 -40,651	-82%	-$510K	﹤0.01%	2227
2022 Q4	$525K	Buy	+49,640	New	+$401K	﹤0.01%	1997
2021 Q1	–	Sell	-93,740	Closed	-$1.59M	–	2781
2020 Q4	$1.59M	Sell	93,740 -39,342	-30%	-$590K	﹤0.01%	1591
2020 Q3	$1.71M	Sell	133,082 -2,958	-2%	-$37.4K	﹤0.01%	1499
2020 Q2	$1.92M	Buy	136,040 +123,166	+957%	+$1.56M	﹤0.01%	1443
2020 Q1	$118K	Buy	+12,874	New	+$166K	﹤0.01%	2492
2019 Q4	–	Sell	-4,305	Closed	-$29K	–	3485
2019 Q3	$29K	Buy	+4,305	New	+$43.5K	﹤0.01%	2921

Other funds holding PRVB

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Victory Capital Management's PRVB Position: Q2 2023 in Review

Victory Capital Management sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 8,989 shares — an estimated $217K sold.

Victory Capital Management first reported a position in PRVB in Q3 2019 and held it in 7 quarters. The position peaked at $1.92M in Q2 2020. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

Victory Capital Management reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Victory Capital Management sold 8,989 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $217K.
Victory Capital Management first reported a position in Provention Bio, Inc. Common Stock in Q3 2019 and held it in 7 quarters.
Victory Capital Management's Provention Bio, Inc. Common Stock position peaked at $1.92M in Q2 2020.
1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on Victory Capital Management's 13F filing for Q2 2023, filed 27 Jul 2023.